Nature, Published online: 19 December 2022; doi:10.1038/d41586-022-04448-z
Assessment of a tumour’s mutational profile offers a way of predicting a person’s response to anticancer therapies called immune-checkpoint inhibitors. It seems that such approaches might fall short for people who are not of European ancestry.
Source link